Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease

Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease

Key points 1. This is one of the very few prospective trials focusing on refractory multiple myeloma with extramdedullary disease (EMD). 2. We successfully laid grounds for implementing immunochemotherapy in EMD treatment.

Bibliographic Details
Main Authors: Ja Min Byun, Chang-Ki Min, Kihyun Kim, Soo-Mee Bang, Je-Jung Lee, Jin Seok Kim, Sung-Soo Yoon, Youngil Koh
Format: Article
Language:English
Published: BMC 2022-10-01
Series:Journal of Hematology & Oncology
Subjects:
Multiple myeloma
Relapse/refractory
Extramedullary multiple myeloma
Daratumumab
DCEP
Online Access:https://doi.org/10.1186/s13045-022-01374-5

Internet

https://doi.org/10.1186/s13045-022-01374-5

Similar Items